Abstract
Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Mini-Reviews in Medicinal Chemistry
Title: Structural Diversity of Neuritogenic Substances and their Application Perspective
Volume: 11 Issue: 8
Author(s): J. Qi, Y. Luo and L. Gao
Affiliation:
Keywords: Neuritogenic substance, Alzheimer's disease, natural products, neurotrophic factors, nerve growth factor, neuronal cells, Aging, SARs, drug development, neuroprotective, terpenoids
Abstract: Small molecular weight substances are functional, as neurotrophic factors can be developed as therapeutic drugs to treat neurodegenerative disorder. Recently, a large number of natural and synthetic neuritogenic compounds have been discovered. These compounds have various structural features, including terpenoids, lipids, alkaloids, steroid glycosides, small molecular peptides, and so on. Some of them possess not only neurotrophic properties but also neuroprotective activities. The structure-activity relationships (SARs) and mechanism of action of some important compounds have been studied intensively. Increasing experimental evidence suggests that several of these compounds can be promising candidates for drug development.
Export Options
About this article
Cite this article as:
Qi J., Luo Y. and Gao L., Structural Diversity of Neuritogenic Substances and their Application Perspective, Mini-Reviews in Medicinal Chemistry 2011; 11 (8) . https://dx.doi.org/10.2174/138955711796268796
DOI https://dx.doi.org/10.2174/138955711796268796 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Reactive Oxygen Species, Redox Signaling and Neuroinflammation in Alzheimer's Disease: The NF-κB Connection
Current Topics in Medicinal Chemistry Dietary Polyphenols and Mitochondrial Function: Role in Health and Disease
Current Medicinal Chemistry From Biomarkers to Cytokine-like Hormones: Uncovering New Directives for Cognitive Loss and Alzheimer’s Disease
Current Neurovascular Research Serotonin 5-HT<sub>4</sub> Receptors: A New Strategy for Developing Fast Acting Antidepressants?
Current Pharmaceutical Design Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Tandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
CNS & Neurological Disorders - Drug Targets Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Tuning and Fine-Tuning of Synapses with Adenosine
Current Neuropharmacology Effects of Proteoglycans on Oxidative/Nitrative Stress
Current Organic Chemistry Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Gut Permeability and Microbiota in Parkinson’s Disease: Role of Depression, Tryptophan Catabolites, Oxidative and Nitrosative Stress and Melatonergic Pathways
Current Pharmaceutical Design Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets ApoE4 May be a Promising Target for Treatment of Coronary Heart Disease and Alzheimer's Disease
Current Drug Targets Assessment of the Effect of Macromolecular Crowding on Aggregation Behaviour of a Model Amyloidogenic Peptide
Protein & Peptide Letters Merging Transport Data for Choroid Plexus with Blood-Brain Barrier to Model CNS Homeostasis and Disease More Effectively
CNS & Neurological Disorders - Drug Targets Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?
Current Medicinal Chemistry Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Epilepsy, Regulation of Brain Energy Metabolism and Neurotransmission
Current Medicinal Chemistry Properties of Neurotoxic Peptides Related to the Bri Gene
Protein & Peptide Letters Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Current Genomics